Overview

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Status:
Unknown status

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the activity and safety of second-line adjuvant therapy with nab-paclitaxel plus gemcitabine (AG) versus oxaliplatin plus folinic acid and fluorouracil (OFF) for gemcitabine-refractory pancreatic cancer after curative resection.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Albumin-Bound Paclitaxel
Fluorouracil
Folic Acid
Gemcitabine
Leucovorin
Levoleucovorin
Oxaliplatin
Paclitaxel